NO20013493L - Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser - Google Patents

Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser

Info

Publication number
NO20013493L
NO20013493L NO20013493A NO20013493A NO20013493L NO 20013493 L NO20013493 L NO 20013493L NO 20013493 A NO20013493 A NO 20013493A NO 20013493 A NO20013493 A NO 20013493A NO 20013493 L NO20013493 L NO 20013493L
Authority
NO
Norway
Prior art keywords
neurotrophin
analogues
treatment
hypomotility disorders
gastrointestinal hypomotility
Prior art date
Application number
NO20013493A
Other languages
English (en)
Other versions
NO20013493D0 (no
NO329488B1 (no
Inventor
Jesse M Cedarbaum
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NO20013493D0 publication Critical patent/NO20013493D0/no
Publication of NO20013493L publication Critical patent/NO20013493L/no
Publication of NO329488B1 publication Critical patent/NO329488B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20013493A 1999-01-15 2001-07-13 Anvendelse av neurotrofin-3 ved fremstilling av et medikament til behandling av gastrointestinale hypomotilitetslidelser. NO329488B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/232,171 US6656474B1 (en) 1999-01-15 1999-01-15 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
PCT/US2000/000682 WO2000041719A1 (en) 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Publications (3)

Publication Number Publication Date
NO20013493D0 NO20013493D0 (no) 2001-07-13
NO20013493L true NO20013493L (no) 2001-09-17
NO329488B1 NO329488B1 (no) 2010-10-25

Family

ID=22872143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013493A NO329488B1 (no) 1999-01-15 2001-07-13 Anvendelse av neurotrofin-3 ved fremstilling av et medikament til behandling av gastrointestinale hypomotilitetslidelser.

Country Status (13)

Country Link
US (1) US6656474B1 (no)
EP (1) EP1146899B1 (no)
JP (1) JP4489303B2 (no)
AT (1) ATE345811T1 (no)
AU (1) AU775860B2 (no)
CA (1) CA2360252C (no)
DE (1) DE60031951D1 (no)
IL (2) IL144315A0 (no)
NO (1) NO329488B1 (no)
NZ (1) NZ512968A (no)
TR (2) TR200201875T2 (no)
WO (1) WO2000041719A1 (no)
ZA (1) ZA200105799B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
AU2001271422B2 (en) * 2000-06-22 2005-12-22 Genentech, Inc. Agonist anti-trk-C monoclonal antibodies
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN105307670A (zh) 2013-06-26 2016-02-03 埃克西金炎症有限公司 Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US5962404A (en) * 1989-08-28 1999-10-05 Yeda Research & Development Co., Ltd. Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
WO1994006455A1 (en) * 1992-09-14 1994-03-31 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
ES2276393T3 (es) * 1994-04-25 2007-06-16 Genentech, Inc. Cardiotrofina y sus usos.
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6211142B1 (en) 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP3540912B2 (ja) * 1997-03-28 2004-07-07 京セラ株式会社 釣糸用ガイド部材
CA2286558A1 (en) 1997-04-25 1998-11-05 Genentech, Inc. Ngf variants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor

Also Published As

Publication number Publication date
NZ512968A (en) 2003-09-26
EP1146899B1 (en) 2006-11-22
IL144315A0 (en) 2002-05-23
TR200201875T2 (tr) 2002-09-23
WO2000041719A9 (en) 2001-08-30
JP2002534479A (ja) 2002-10-15
EP1146899A1 (en) 2001-10-24
NO20013493D0 (no) 2001-07-13
DE60031951D1 (de) 2007-01-04
CA2360252A1 (en) 2000-07-20
CA2360252C (en) 2010-11-02
ZA200105799B (en) 2002-01-24
EP1146899A4 (en) 2003-03-05
JP4489303B2 (ja) 2010-06-23
WO2000041719A1 (en) 2000-07-20
AU775860B2 (en) 2004-08-19
US6656474B1 (en) 2003-12-02
AU2963600A (en) 2000-08-01
TR200102767T2 (tr) 2002-04-22
IL144315A (en) 2008-08-07
ATE345811T1 (de) 2006-12-15
NO329488B1 (no) 2010-10-25

Similar Documents

Publication Publication Date Title
NO20013493L (no) Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser
NO20013554D0 (no) Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
HK1069767A1 (en) Methods for inhibiting ocular processes
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
CY1109650T1 (el) Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
BR0106411B1 (pt) processo de tratamento do lìquido residual de cromatização.
BR0209990A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60018393D1 (de) Oberflächenbehandlungsverfahren und damit behandelter zylinderkopf
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
NO20012423D0 (no) Antikonvulsjonsmiddelderivater som er nyttige ved behandling av posttraumatiske stresslidelser
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
BR9704009A (pt) Processo de remoção de terpeno de borras de café
DE60017366D1 (de) Zugabe von behandlungsmitteln bei festphasenpolymerisationsverfahren
ATE345818T1 (de) S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
WO2001087305A3 (en) Method for treating functional dyspepsia using alosetron
UA33439A (uk) Спосіб інтенсивного лікування шизофренії
UA32314A (uk) Спосіб лікування некротичного панкреатиту
MXPA03010632A (es) Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos.
UA33531A (uk) Спосіб терапії шизофренії

Legal Events

Date Code Title Description
MK1K Patent expired